CMC · Manufacturing · CDMO

A clear route from process to clinical product

Almira Biotech Consultancy helps biotech companies and investors make the technical and strategic decisions around CMC, manufacturing and CDMO partnerships — independent, practical and with an eye for both quality and timelines.

  • StrategyA CMC roadmap aligned with clinical and business milestones
  • ExecutionSelection and management of CDMO partners
  • AssessmentDossier review and technical due diligence

Services

Support at every stage of development and manufacturing

From a first CMC plan to the assessment of a manufacturing platform: support per question, as a short assignment or as longer-term engagement.

01

CMC strategy

A CMC plan that fits your clinical path, budget and timeline — with clear choices on process, analytics and phasing.

  • CMC roadmap and gap analysis
  • Phase-appropriate quality and analytical strategy
  • Clear view of risks and critical decision points
02

Biopharmaceutical manufacturing

Advice on process development, scale-up and manufacturing strategy for biological products, from lab scale to GMP production.

  • Process design and scale-up questions
  • Technology transfer and GMP readiness
  • Manufacturing platform and capacity choices
03

CDMO selection

A structured selection process to find the CDMO that fits your programme technically, from a quality perspective and commercially.

  • Requirements, RFI and RFP
  • Evaluation of proposals and quotes
  • Comparison and well-founded recommendation
04

CDMO project management

Managing the collaboration with your CDMO, so that scope, timelines and deliverables stay clear and issues surface early.

  • Defining and tracking scope and timelines
  • Technical representation in project meetings
  • Review of batch documentation and reports
05

IND dossier review

A critical review of the CMC sections (Module 3 / quality) of your IND dossier before it goes to the regulator.

  • Consistency and completeness of CMC data
  • Anticipating potential regulator questions
  • Concrete recommendations for additions
06

Technical due diligence

An independent assessment of technology, process and CMC position — for investors, partners or in an acquisition.

  • Assessment of process, scalability and risks
  • Analysis of manufacturing and CMC readiness
  • Findings in a clear report
Portrait of Alfred Luitjens
Alfred Luitjens Biotech Consultant

About

More than 40 years in vaccine and biopharmaceutical manufacturing

I am Alfred Luitjens, owner of Almira Biotech Consultancy. I have more than 40 years of global experience building and leading diverse teams within vaccine and biopharmaceutical manufacturing organisations.

My expertise lies in GMP manufacturing, process development, regulatory strategy and technical leadership. Throughout my career I have focused on delivering biopharmaceutical products in line with current GMP regulations, with reliability and cost-effectiveness as guiding principles — and on advancing therapies from early-stage development through clinical trials.

I work according to principles of integrity, science and results. Innovation is one of the key drivers for bringing business value.

Current position
Owner, Almira Biotech Consultancy
Qualifications
HBO-B, HBO-A, MBO (University of Applied Sciences, medical & microbiology)
Languages
English (fluent), Dutch (native)

Key experience

  1. 2025 – present
    Almira Biotech Consultancy Owner

    Applying more than 40 years of expertise in vaccine and viral vector process development, analytical development and GMP manufacturing. Focus on helping university spin-offs and research teams take their products into Phase 1 and Phase 2 clinical trials, and on supporting business development teams, CDMOs and innovators. Hands-on support covers platform development, CMC strategy, quality and regulatory strategy, and GMP manufacturing planning and execution.

  2. Jul 2025 – present
    PacingCure Consultant

    Executing the Product Development Plan developed with MHPM-Services, focused on selecting a CDMO partner for process and analytical development and subsequent GMP manufacturing of PacingCure's first AAV gene therapy product.

  3. Mar 2025 – present
    Biopharm Services Associate Consultant

    CMC support, model-building support and assistance in client relationship building.

  4. Jan 2025 – May 2025
    MHPM-Services Consultant

    Developed a Product Development Plan for an AAV gene therapy product, in collaboration with MHPM-Services and the Dutch start-up PacingCure.

  5. 2018 – present
    IKA-Werke GmbH & Co. KG Consultant

    Consultant for IKA's Bio Processing Solution business unit, focusing on the design of bioprocess equipment and the application of biotechnology.

  6. 2019 – Sep 2025
    Batavia Biosciences Global Technical Sales Director

    Responsible for business development and member of the management team (2019–2022). Planned and implemented global sales activities and built the commercial business development team. Responsible for not-for-profit clients such as IAVI, CEPI, BMGF and PATH, generating more than 60% of Batavia's sales since 2022 (an average of €18M per year). CMC Head for all IAVI projects since December 2024, leading a multifunctional team towards Phase 3 preparation and manufacturing for VSV-Lassa and Phase 1/2 manufacturing for VSV-Ebola Sudan and VSV-Marburg.

  7. 2015 – 2018
    Batavia Biosciences Director Cell Technology

    Led the upstream development team of 10 scientists and technicians, managed the team developing a Phase 1 process for a Chikungunya vaccine, and provided technical support to business development, including technical quotations for new clients.

  8. 2014 – 2015
    GSK Vaccines Senior Manager, Process Architecture Improvement

    Set up the Process Architecture Improvement (PAI) team, improving production processes across the end-to-end product chain. Business cases showed that a €10M investment in a redeveloped Malaria RTS,S process would pay back more than €400M over 20 years, and that a bioreactor system for Hepatitis A would deliver a €100M benefit over a 20-year lifetime. Involved in GSK's Crossbow remediation project; author and leader of the MRC-5 cell characterisation project.

  9. 2012 – 2014
    Crucell CMC Leader, New Technology

    Technical and scientific leader for the development of an intensified inactivated polio vaccine process, leading a team of 60 across upstream, downstream and analytical development. Managed outsourcing to Batavia Biosciences, Bilthoven Biologics and NIBSC, and technology transfer of the production process to Crucell Stockholm.

  10. 2009 – 2011
    Crucell Senior Scientist, New Technology

    Set up the team for FluMab antibody process development at Crucell and Xcellerex (Marlborough, USA), and was scientific leader at Xcellerex. Involved in the FlexFactory, the XDR10 bioreactor, facility layout, and the invention of the fully single-use PACS perfusion system.

  11. 2007 – 2009
    Crucell Senior Scientist, Upstream Development

    Inventor of the Process Intensification (PIN) process for rAd35 (EP 2350268B1) and rAd26 (WO 2011098592 A1) vaccines. The PIN process is used at Crucell for the production of Ebola, TB, polio and influenza vaccines.

Show earlier career (1982 – 2006)
  1. 2004 – 2006
    Crucell Scientist, Upstream Development

    Led upscaling of the PER.C6 cell-based influenza vaccine process in collaboration with sanofi pasteur, including installation, validation and operation of a 100L fermentation production room and technology transfer.

  2. 2002 – 2004
    DSM Biologics Process Engineer, cGMP Operations

    Managed the qualification and operation of a 250L perfusion production system, worked with international clients, served on the deviation board and was involved in an FDA inspection for a client's product approval.

  3. 1997 – 2002
    ID-Lelystad Plant Manager, Foot-and-Mouth Disease Vaccine Production

    Managed the BSL-3 FMD vaccine production plant and its cGMP compliance, achieved a six-fold improvement in the first year, and led the transfer to a new 2000L production plant.

  4. 1994 – 1997
    Solvay Duphar Process Engineer, Research & Development

    Developed and scaled up upstream processes for Marek's Disease vaccine (QT35 cells) and Equine Influenza vaccine (MDCK cells).

  5. 1988 – 1994
    Solvay Duphar Team Leader, Biological Production

    Led bulk manufacturing of cell- and egg-based veterinary vaccines, managing 9–11 operators.

  6. 1982 – 1988
    Solvay Duphar Vaccine Developer, R&D Animal Health

    QC testing, process optimisation and development of inactivated and live viral veterinary vaccines.

Key projects

  • Led global teams for vaccine and viral vector development and manufacturing.
  • Drove process innovations resulting in significant cost reductions (e.g. vaccines at GSK).
  • Supported multinational collaborations and partnerships for clinical trial readiness.
  • Published key work in manufacturing process and vaccine development (e.g. rotavirus vaccine process).

Publications

  1. 2024
    Production and purification of recombinant proteins.A. Luitjens, E. van Corven · Pharmaceutical Biotechnology, 6th edition, chapter 4doi:10.1007/978-3-031-30023-3_4
  2. 2021
    Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine.A. Hamidi, F. Hoeksema, P. Velthof, A. Lemckert, G. Gillissen, A. Luitjens, J.E. Bines, S.R. Pullagurla, P. Kumar, D.B. Volkin, S.B. Joshi, M. Havenga, W.A.M. Bakker, C. Yallop · Vaccine 03.033doi:10.1016/j.vaccine.2021.03.033
  3. 2019
    Production and purification of recombinant proteins.A. Luitjens, E. van Corven · Pharmaceutical Biotechnology, 5th edition, chapter 4doi:10.1007/978-3-030-00710-2_4
  4. 2018
    Enhancing viral vaccine production using engineered knockout Vero cell lines – a second look.F. Hoeksema, J. Karpilow, A. Luitjens, F. Lagerwerf, M. Havenga, M. Groothuizen, G. Gillissen, A.A.C. Lemckert, B. Jiang, R.A. Tripp, C. Yallop · Vaccine 36(16), 2093–2103doi:10.1016/j.vaccine.2018.03.010
  5. 2013
    Production and purification of recombinant proteins.F. Kadir, P. Ives, A. Luitjens, E. van Corven · Pharmaceutical Biotechnology, 4th edition, chapter 3doi:10.1007/978-1-4614-6486-0_3
  6. 2013
    Affordable vaccines for developing nations: fact or fiction?A. Luitjens, E. van Corven · Pharmaceutical Bioprocessing 1(2), 129–131doi:10.4155/pbp.13.20
  7. 2013
    PER.C6® cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine.B.P. Sanders, D. Edo Matas, J. Custers, M.H. Koldijk, V. Klaren, M. Turk, A. Luitjens, W.A.M. Bakker, F. Uytdehaag, J. Goudsmit, J.A. Lewis, H. Schuitemaker · Vaccine 31(5), 850–856doi:10.1016/j.vaccine.2012.10.070
  8. 2012
    Single-use biotechnologies and modular manufacturing environments invite paradigm shifts in bioprocess development and biopharmaceutical manufacturing.A. Luitjens, J.A. Lewis, A. Pralong · Biopharmaceutical Production Technology, chapter 26doi:10.1002/9783527653096.ch26
  9. 2010
    Going fully disposable – current possibilities: a case study from Crucell.A. Luitjens, A. Pralong · Single-Use Technology in Biopharmaceutical Manufacture, chapter 29doi:10.1002/9780470909997.ch29
  10. 1994
    A novel non-mineral oil-based adjuvant. 2. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in pigs.L.A.Th. Hilgers, P.I.I. Platenburg, A. Luitjens, B. Groenveld, T. Dazelle, M. Ferrai-Laloux, M.M. Weststrate · Vaccine 12doi:10.1016/0264-410x(94)90273-9
  11. 1994
    A novel non-mineral oil-based adjuvant. 1. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in laboratory animals.L.A.Th. Hilgers, P.I.I. Platenburg, A. Luitjens, B. Groenveld, T. Dazelle, M. Ferrai-Laloux, M.M. Weststrate · Vaccine 12doi:10.1016/0264-410x(94)90272-0

Contact

Let's discuss your project

An introductory conversation comes without obligation. Briefly describe your project or question, and I will get in touch to explore the options.

I use your details only to respond to your message. See the privacy statement.